GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Strata Skin Sciences Inc (NAS:SSKN) » Definitions » Change In Receivables

Strata Skin Sciences (Strata Skin Sciences) Change In Receivables : $0.14 Mil (TTM As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Strata Skin Sciences Change In Receivables?

Strata Skin Sciences's change in receivables for the quarter that ended in Dec. 2023 was $0.27 Mil. It means Strata Skin Sciences's Accounts Receivable declined by $0.27 Mil from Sep. 2023 to Dec. 2023 .

Strata Skin Sciences's change in receivables for the fiscal year that ended in Dec. 2023 was $0.14 Mil. It means Strata Skin Sciences's Accounts Receivable declined by $0.14 Mil from Dec. 2022 to Dec. 2023 .

Strata Skin Sciences's Accounts Receivable for the quarter that ended in Dec. 2023 was $4.44 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Strata Skin Sciences's Days Sales Outstanding for the three months ended in Dec. 2023 was 46.63.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Strata Skin Sciences's liquidation value for the three months ended in Dec. 2023 was $-17.88 Mil.


Strata Skin Sciences Change In Receivables Historical Data

The historical data trend for Strata Skin Sciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strata Skin Sciences Change In Receivables Chart

Strata Skin Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.04 1.35 -0.49 -1.15 0.14

Strata Skin Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.90 0.63 -0.42 -0.33 0.27

Strata Skin Sciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strata Skin Sciences  (NAS:SSKN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Strata Skin Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=4.44/8.689*91
=46.63

2. In Ben Graham's calculation of liquidation value, Strata Skin Sciences's accounts receivable are only considered to be worth 75% of book value:

Strata Skin Sciences's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=6.784-29.328+0.75 * 4.44+0.5 * 2.673
=-17.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strata Skin Sciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Strata Skin Sciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Strata Skin Sciences (Strata Skin Sciences) Business Description

Traded in Other Exchanges
Address
5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.
Executives
Shmuel Gov officer: SVP & General Manager Carlsbad 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Samuel Rubinstein director 5 WALNUT GROVE DR., SUITE 140, HORSHAM PA 19044
Wayne Cafran director 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Irit Yaniv director 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
22nw Gp, Inc. 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw Fund Gp, Llc 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Aron R. English 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw, Lp 10 percent owner 590 1ST AVE S, UNIT C1, SEATTLE WA 98104
22nw Fund, Lp 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Christopher Lesovitz officer: Chief Financial Officer 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Robert Joseph Moccia director, officer: Chief Executive Officer 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Patricia S Walker director 5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Douglas Strang director 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727